同和药业
(300636)
| 流通市值：26.85亿 | | | 总市值：30.81亿 |
| 流通股本：3.67亿 | | | 总股本：4.22亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 186,897,547.53 | 758,890,499.03 | 569,933,408.38 | 382,051,594.68 |
| 营业收入 | 186,897,547.53 | 758,890,499.03 | 569,933,408.38 | 382,051,594.68 |
| 二、营业总成本 | 161,677,017.83 | 626,890,162.6 | 455,177,777.45 | 295,168,592.6 |
| 营业成本 | 135,347,468.09 | 508,368,427.26 | 378,090,930.9 | 250,138,319.2 |
| 税金及附加 | 2,274,797.03 | 7,826,914.18 | 5,380,972.73 | 3,391,661.69 |
| 销售费用 | 5,248,872.85 | 29,938,037.83 | 18,674,206.69 | 12,660,645.86 |
| 管理费用 | 9,298,371.02 | 38,281,977.74 | 26,858,732.18 | 17,444,427.45 |
| 研发费用 | 14,140,941.15 | 59,447,007.04 | 39,204,527.63 | 22,181,806.93 |
| 财务费用 | -4,633,432.31 | -16,972,201.45 | -13,031,592.68 | -10,648,268.53 |
| 其中:利息费用 | 2,988,280.14 | 18,141,989.96 | 13,176,657.04 | 8,911,778.28 |
| 其中:利息收入 | 6,932,846.19 | 30,220,277.53 | 23,114,601.72 | 16,216,862.52 |
| 加:公允价值变动收益 | 36,683.33 | 49,700 | - | - |
| 加:投资收益 | -103,289.22 | 574,934.35 | 606,704.78 | -45,884.66 |
| 资产处置收益 | -104,602.83 | -1,168,164.38 | -706,142.86 | -706,142.86 |
| 资产减值损失(新) | -6,698,790.66 | -26,567,161.93 | -12,375,041.28 | -11,914,375.02 |
| 信用减值损失(新) | -411,904.22 | -1,312,914.78 | -1,860,939.34 | -1,988,189.34 |
| 其他收益 | 4,106,508.64 | 7,824,109.35 | 5,590,954.46 | 4,979,556.11 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 22,045,134.74 | 111,400,839.04 | 106,011,166.69 | 77,207,966.31 |
| 加:营业外收入 | 51.02 | 4,050,034.18 | 1.36 | - |
| 减:营业外支出 | - | 760,965.06 | 512,910.72 | 66,750 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 22,045,185.76 | 114,689,908.16 | 105,498,257.33 | 77,141,216.31 |
| 减:所得税费用 | 1,263,808.79 | 8,105,805.99 | 9,761,795.73 | 7,589,193.91 |
| 六、净利润 | 20,781,376.97 | 106,584,102.17 | 95,736,461.6 | 69,552,022.4 |
| 持续经营净利润 | 20,781,376.97 | 106,584,102.17 | 95,736,461.6 | 69,552,022.4 |
| 归属于母公司股东的净利润 | 20,781,376.97 | 106,584,102.17 | 95,736,461.6 | 69,552,022.4 |
| (一)基本每股收益 | 0.05 | 0.25 | 0.23 | 0.17 |
| (二)稀释每股收益 | 0.05 | 0.25 | 0.23 | 0.17 |
| 九、综合收益总额 | 20,781,376.97 | 106,584,102.17 | 95,736,461.6 | 69,552,022.4 |
| 归属于母公司股东的综合收益总额 | 20,781,376.97 | 106,584,102.17 | 95,736,461.6 | 69,552,022.4 |
| 公告日期 | 2025-04-25 | 2025-04-25 | 2024-10-24 | 2024-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |